FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
REGENXBIO Partners With Nippon Shinyaku in $810M Deal for Hunter and Hurler Syndrome Therapies
Reported Earlier, Eisai And Biogen Announced FDA Acceptance Of LEQEMBI BLA For Weekly Subcutaneous Dosing To Treat Early Alzheimer's Disease
MediciNova Presents Study Update And Interim Analysis Of Phase 2/3 Clinical Trial Of MN-166 In ALS At The 35th International Symposium On ALS/MND
D. Boral Capital Initiates Coverage On MediciNova With Buy Rating, Announces Price Target of $9
MediciNova Analyst Ratings
Reported Wednesday, Eisai and Biogen Introduce LEQEMBI In South Korea To Combat Alzheimer's And Mild Cognitive Impairment
MediciNova Highlights Strategic Focus On Non-Dilutive Funding With NIH-Funded ALS Trial And Canadian Long COVID Study, Reports Strong $42.3M Cash Position, And Reaffirms Commitment To Sustainable Growth And Shareholder Transparency
GRAIL Announces The First Patient Has Been Tested For Eligibility With Its Non-Small Cell Lung Cancer CtDNA Assay In The TROPION-Lung12 Phase 3 Study, Sponsored By AstraZeneca In Collaboration With Daiichi Sankyo
MediciNova Receives Notice Of Allowance From US PTO For A Pending Patent Application For MN-001 (Tipelukast) To Cover 'Method To Decrease Triglyceride Synthesis In A Liver Of A Subject'
MediciNova Says Notified By Sanofi That Sanofi/Novartis Litigation Was Settled; Says It Is Entitled To Receive Certain Amount Of Monetary Damages Through This Settlement
GSK, Pfizer And Shionogi's ViiV Healthcare Expands On Real-World Data Supporting Use Of Long-Acting Therapies In Diverse Patient Populations At HIV Glasgow
Daiichi Sankyo Company, Limited (DSKYF) Q2 2025 Earnings Call Transcript Summary
Reported Earlier, Eisai And Submit LEQEMBI BLA For Subcutaneous Alzheimer's Treatment To FDA, Targeting Early Disease Stages
Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript Summary
Equillium Shares Are Trading Lower After the Company Announced Ono Pharmaceutical Has Made the Business Decision to Allow the Expiration of Its Option to Acquire Equillium's Rights to Itolizumab
Daiichi Sankyo Co Expects FY2024 GAAP EPS Guidance JPY 118.66; FY2024 Sales Guidance JPY 1830B.
Astellas Pharma Inc. (ALPMF) Q2 2024 Earnings Call Transcript Summary
Takeda Pharmaceutical Q2 2024 GAAP EPS ¥134.00 Up From ¥111.00 YoY, Sales ¥.176T Beat ¥1.084T Estimate
Shionogi & Co., Ltd. (SGIOY) Q2 2024 Earnings Call Transcript Summary